drugset

drugset / Trial / NCT02650895

Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)

NCT02650895 ↗

Phase 1 Completed 40 enrolled Merck & Co., Inc. National Institute of Neurological Disorders and Stroke (NINDS) · collab

RandomizedParallel-groupDouble-blindOther

Summary

The purpose of this study is to evaluate the safety and tolerability of single ascending intravenous (IV) doses of efprezimod alfa in healthy adult participants.

Timeline

Start: 2014-06-02
Primary completion: 2015-01-15
Completion: 2015-01-15

Publications

Wang X, Liu M, Zhang J, Brown NK, Zhang P, Zhang Y, Liu H, Du X, Wu W, Devenport M, Tao W, Mao-Draayer Y, Chen GY, Chen YE, Zheng P, Liu Y. CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder. Cell Metab. 2022 Aug 2;34(8):1088-1103.e6. doi: 10.1016/j.cmet.2022.07.005.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CD24Fc	Protein / enzyme biologic	10 mg	Intravenous
Subject	CD24Fc	Protein / enzyme biologic	30 mg	Intravenous
Subject	CD24Fc	Protein / enzyme biologic	60 mg	Intravenous
Subject	CD24Fc	Protein / enzyme biologic	120 mg	Intravenous
Subject	CD24Fc	Protein / enzyme biologic	240 mg	Intravenous

Indications

No indication recorded.